Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting. Leerink Partners 2026 Global Healthcare ConferenceDate: March 8-11, 2026Location: W South Beach, Miami, FLFormat: One-on-one investor meetings Investors registered to attend the conference who w
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026GlobeNewswire
- Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory BoardGlobeNewswire
- Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium [Yahoo! Finance]Yahoo! Finance
- Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology SymposiumGlobeNewswire
PALI
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- PALI's page on the SEC website